Adaptive Biotechnologies (ADPT) EBIAT (2018 - 2025)
Historic EBIAT for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $9.5 million.
- Adaptive Biotechnologies' EBIAT rose 12974.11% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.6 million, marking a year-over-year increase of 5923.26%. This contributed to the annual value of -$159.6 million for FY2024, which is 2916.46% up from last year.
- Adaptive Biotechnologies' EBIAT amounted to $9.5 million in Q3 2025, which was up 12974.11% from -$25.6 million recorded in Q2 2025.
- Adaptive Biotechnologies' EBIAT's 5-year high stood at $9.5 million during Q3 2025, with a 5-year trough of -$69.5 million in Q4 2023.
- In the last 5 years, Adaptive Biotechnologies' EBIAT had a median value of -$47.5 million in 2024 and averaged -$44.1 million.
- Per our database at Business Quant, Adaptive Biotechnologies' EBIAT plummeted by 7293.68% in 2023 and then skyrocketed by 12974.11% in 2025.
- Quarter analysis of 5 years shows Adaptive Biotechnologies' EBIAT stood at -$61.4 million in 2021, then surged by 34.53% to -$40.2 million in 2022, then tumbled by 72.94% to -$69.5 million in 2023, then skyrocketed by 51.46% to -$33.7 million in 2024, then skyrocketed by 128.31% to $9.5 million in 2025.
- Its EBIAT stands at $9.5 million for Q3 2025, versus -$25.6 million for Q2 2025 and -$29.9 million for Q1 2025.